Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02163889 · ClinicalTrials.gov registry record

Serial Therapeutic and Antifungal Monitoring Protocol

A clinical trial, sponsored by T2 Biosystems.

Completed
Registry status
31
Enrollment target

NCT02163889 is a clinical trial that has completed, run by T2 Biosystems. The registered enrollment target is 31 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02163889 has completed, sponsored by T2 Biosystems.

COMPLETED
Registry status
31 participants
Enrollment target

Study Summary

The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture. This study will collect a T2clinical specimen and companion blood culture from patients who have exhibited a positive blood culture by gram stain for yeast, and who are receiving treatment with antifungal therapy.

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2014-09
Est. Completion 2017-04

Sponsor

T2 Biosystems

7 total trials

What the Registry Record Tells You About NCT02163889

The ClinicalTrials.gov registry entry for NCT02163889 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is T2 Biosystems, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02163889 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02163889 about?

NCT02163889 is a clinical study titled "Serial Therapeutic and Antifungal Monitoring Protocol". The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture. This study will collect a T2clinical specimen and companion blood culture from patients who have exhibited a positive blood culture by gram stain...

What is the current status of trial NCT02163889?

This trial is currently completed. The enrollment target is 31 participants. The study started on 2014-09. Estimated completion is 2017-04.

Who is sponsoring clinical trial NCT02163889?

This trial is sponsored by T2 Biosystems, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.